Protagonist Therapeutics, Inc
Protagonist Therapeutics, Inc (PTGX): 8 pipeline candidates · 1 upcoming catalyst · ~34 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
33.7 months
D/E 0.06 · 10% dilution
Lead: BLA Filed
8 candidates
1 upcoming, next in ~5633d
0 buys · 26 sells (180d)
A transparent, data-derived signal for Protagonist Therapeutics, Incacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$7.2B
Cash
$194.0M
Quarterly Burn
$48.9M
Runway
33.7 mo
Revenue
$56.4M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (8 candidates)
| Drug | Phase |
|---|---|
| AmylinR-based agonists | Preclinical |
| Icotyde | BLA Filed |
| Oral IL-4R alpha antagonist | Preclinical |
| PN-458 | Preclinical |
| PN-477 | Preclinical |
| PN-8047 | Preclinical |
| PN-881 | Phase 1 |
| Rusfertide | Phase 3 |
Upcoming Catalysts (1)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
320
Total value held
$8.15B
| Holder | Shares | Value |
|---|---|---|
| blackrock, inc. | 9,779,369 | $1.03B |
| farallon capital management llc | 6,348,906 | $669.2M |
| janus henderson group plc | 5,783,054 | $609.7M |
| rtw investments, lp | 5,059,053 | $533.2M |
| wellington management group llp | 3,599,644 | $379.4M |
| vanguard portfolio management llc | 3,481,211 | $366.9M |
| state street corp | 3,116,749 | $328.5M |
| woodline partners lp | 2,828,346 | $298.1M |
| vanguard capital management llc | 2,805,896 | $295.7M |
| perceptive advisors llc | 2,461,758 | $259.5M |
Showing top 10 of 320 institutional holders of Protagonist Therapeutics, Inc. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Protagonist Therapeutics, Inc's pipeline?
Protagonist Therapeutics, Inc (PTGX) has 8 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Protagonist Therapeutics, Inc's lead drug candidate?
Protagonist Therapeutics, Inc's most advanced tracked candidate is AmylinR-based agonists (Preclinical) for Obesity.
What is Protagonist Therapeutics, Inc's next catalyst?
Protagonist Therapeutics, Inc's next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: ICOTYDE" — expected November 19, 2041.
What is Protagonist Therapeutics, Inc's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Protagonist Therapeutics, Inc has approximately 33.7 months of cash runway.
What is Protagonist Therapeutics, Inc's market capitalization?
Protagonist Therapeutics, Inc's market capitalization is approximately $7.2B.
Get the full picture on Protagonist Therapeutics, Inc
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.